GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » ROE %

APGE (Apogee Therapeutics) ROE % : -26.00% (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Apogee Therapeutics's annualized net income for the quarter that ended in Sep. 2024 was $-196.07 Mil. Apogee Therapeutics's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $754.02 Mil. Therefore, Apogee Therapeutics's annualized ROE % for the quarter that ended in Sep. 2024 was -26.00%.

The historical rank and industry rank for Apogee Therapeutics's ROE % or its related term are showing as below:

APGE' s ROE % Range Over the Past 10 Years
Min: -28   Med: -27.01   Max: -21.13
Current: -21.13

During the past 2 years, Apogee Therapeutics's highest ROE % was -21.13%. The lowest was -28.00%. And the median was -27.01%.

APGE's ROE % is ranked better than
65.36% of 1305 companies
in the Biotechnology industry
Industry Median: -43.68 vs APGE: -21.13

Apogee Therapeutics ROE % Historical Data

The historical data trend for Apogee Therapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics ROE % Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23
ROE %
-28.00 -26.02

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.14 -25.27 -17.58 -15.63 -26.00

Competitive Comparison of Apogee Therapeutics's ROE %

For the Biotechnology subindustry, Apogee Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apogee Therapeutics's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where Apogee Therapeutics's ROE % falls into.



Apogee Therapeutics ROE % Calculation

Apogee Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-83.985/( (142.075+503.354)/ 2 )
=-83.985/322.7145
=-26.02 %

Apogee Therapeutics's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-196.072/( (773.639+734.402)/ 2 )
=-196.072/754.0205
=-26.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Apogee Therapeutics  (NAS:APGE) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-196.072/754.0205
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-196.072 / 0)*(0 / 788.4715)*(788.4715 / 754.0205)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0457
=ROA %*Equity Multiplier
=N/A %*1.0457
=-26.00 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-196.072/754.0205
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-196.072 / -196.072) * (-196.072 / -234.744) * (-234.744 / 0) * (0 / 788.4715) * (788.4715 / 754.0205)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.8353 * N/A % * 0 * 1.0457
=-26.00 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Apogee Therapeutics ROE % Related Terms

Thank you for viewing the detailed overview of Apogee Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Apogee Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
Executives
Michael Thomas Henderson director, officer: Chief Executive Officer 421 KIPLING STREET, PALO ALTO CA 94301
Carl Dambkowski officer: Chief Medical Officer 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453
Jane Henderson officer: Chief Financial Officer C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Mark C. Mckenna director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Peter Evan Harwin director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr director NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Fairmount Healthcare Fund L.p. director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener director 3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428